GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain
This article was originally published in The Pink Sheet Daily
British pharma pulls application for MS spasticity but says it will re-file in U.K. after confirmatory study.
You may also be interested in...
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.